Vaxart Inc Quick Ratio (VXRT) starting from the second quarter 2026 to second quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Vaxart Inc   (VXRT)

Vaxart Inc 's Quick Ratio

VXRT's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Vaxart Inc 's Cash & cash equivalent grew by 649.88 % in the Q2 2026 sequentially, while Current Liabilities decreased, this led to improvement in Vaxart Inc 's Quick Ratio to 1.05, Quick Ratio remained below Vaxart Inc average.

Within Biotechnology & Pharmaceuticals industry 112 other companies have achieved higher Quick Ratio than Vaxart Inc in second quarter 2026. While Quick Ratio total ranking has improved so far during the Q2 2026 to 3693, from total ranking in the first quarter 2026 at 4622.

Explain Quick Ratio?
How much Cash & cash equivalents VXRT´s has?
What are VXRT´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

VXRT Quick Ratio (Jun 30 2026)
Q2		 (Mar 31 2026)
Q1		 (Dec 31 2025)
Q4		 (Sep 30 2025)
Q3		 (Jun 30 2025)
Q2
Y / Y Current Liabilities Change -37.98 % -21.99 % -4.54 % 110.67 % 648.15 %
Y / Y Cash & cash equivalent Change 1150.94 % -22.39 % -62.28 % -67.52 % -68.1 %
Quick Ratio MRQ 1.05 0.13 0.12 0.07 0.05
VXRT's Total Ranking # 3693 # 4622 # 4714 # 4912 # 4400
Seq. Current Liabilities Change -4.86 % -11.43 % -48.76 % 43.62 % 19.67 %
Seq. Cash & cash equivalent Change 649.88 % 2.83 % -16.12 % 93.39 % -53.47 %



Quick Ratio second quarter 2026 Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 113
Healthcare Sector # 617
Overall Market # 1921


Quick Ratio Statistics
High Average Low
26.24 4.4 0.05
(Mar 31 2012)   (Jun 30 2025)




Financial Statements
Vaxart Inc 's Current Liabilities $ 73 Millions Visit VXRT's Balance sheet
Vaxart Inc 's Cash & cash equivalent $ 77 Millions Visit VXRT's Balance sheet
Source of VXRT's Sales Visit VXRT's Sales by Geography


Cumulative Vaxart Inc 's Quick Ratio

VXRT's Quick Ratio for the trailling 12 Months

VXRT Quick Ratio

 (Jun 30 2026)
12 Months		 (Mar 31 2026)
12 Months		 (Dec 31 2025)
12 Months		 (Sep 30 2025)
12 Months		 (Jun 30 2025)
12 Months
Y / Y Current Liabilities TTM Growth 4.74 % 57.89 % 134.91 % 284.44 % 606.51 %
Y / Y Cash & cash equivalent TTM Growth 32.3 % -59.94 % -55.3 % -18.43 % 52.92 %
Quick Ratio TTM 0.27 0.09 0.09 0.12 0.21
Total Ranking TTM # 2218 # 2751 # 2166 # 1841 # 1419
Seq. Current Liabilities TTM Growth -9.93 % -4.59 % -0.87 % 22.94 % 35.77 %
Seq. Cash & cash equivalent TTM Growth 184.91 % -7.18 % -28.54 % -29.99 % -13.74 %

Quick ratio ranking by company, industry and sector >> Back to VXRT Financial Strength Comparisons >> Go to Compare VXRT Quick Ratio to its Competitors

On the trailing twelve months basis VXRT Cash & cash equivalent more than doubled by 1150.94 % in Q2 2026 year on year, while Current Liabilities decreased to $73 millions, this led to increase in in Vaxart Inc 's Quick Ratio to 0.27, Quick Ratio remained below VXRT average.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Biotechnology & Pharmaceuticals industry 142 other companies have achieved higher Quick Ratio than Vaxart Inc . While Quick Ratio overall ranking has improved so far to 0, from total ranking during the twelve months ending first quarter 2026 at 3991.

Explain Quick Ratio?
How much Cash & cash equivalents VXRT´s has?
What are VXRT´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Biotechnology & Pharmaceuticals Industry # 143
Healthcare Sector # 902
Within the Market # 3693


trailing twelve months Quick Ratio Statistics
High Average Low
17.86 4.84 0.31
(Sep 30 2012)   (Sep 30 2025)




Companies with similar Quick Ratio in the quarter ending Jun 30 2026, within Biotechnology & Pharmaceuticals Industry Quick RatioJun 30 2026 MRQ Cash & cash equivalentJun 30 2026 MRQ Current Liabilities
Moderna Inc   2.73 $ 6,910.000  Millions$ 2,534.000  Millions
Sana Biotechnology Inc   2.59 $ 320.990  Millions$ 123.752  Millions
Tarsus Pharmaceuticals Inc   2.56 $ 449.690  Millions$ 175.753  Millions
Meiragtx Holdings Plc  2.46 $ 143.166  Millions$ 58.096  Millions
Kodiak Sciences Inc   2.39 $ 125.903  Millions$ 52.770  Millions
Exelixis Inc   2.32 $ 839.385  Millions$ 361.927  Millions
Precision Biosciences Inc  2.19 $ 87.549  Millions$ 39.886  Millions
Novavax inc   2.18 $ 719.340  Millions$ 330.574  Millions
Regenxbio Inc   2.11 $ 174.530  Millions$ 82.621  Millions
Biocardia Inc   2.00 $ 4.117  Millions$ 2.055  Millions
Kymera Therapeutics Inc   1.75 $ 124.477  Millions$ 71.326  Millions
Biocryst Pharmaceuticals Inc   1.69 $ 353.279  Millions$ 208.846  Millions
Coherus Oncology inc   1.69 $ 127.683  Millions$ 75.510  Millions
Bio techne Corp  1.62 $ 264.712  Millions$ 163.700  Millions
Atara Biotherapeutics Inc   1.45 $ 9.900  Millions$ 6.847  Millions
Twist Bioscience Corporation  1.39 $ 166.839  Millions$ 120.255  Millions
Neumora Therapeutics Inc   1.34 $ 116.834  Millions$ 87.478  Millions
Calidi Biotherapeutics Inc   1.33 $ 4.290  Millions$ 3.237  Millions
Passage Bio Inc   1.17 $ 24.155  Millions$ 20.719  Millions
Mink Therapeutics Inc   1.16 $ 8.807  Millions$ 7.569  Millions
Amgen Inc   1.07 $ 27,404.000  Millions$ 25,502.000  Millions
Aligos Therapeutics Inc   1.07 $ 30.381  Millions$ 28.343  Millions
Vaxart Inc   1.05 $ 77.058  Millions$ 73.108  Millions
Iovance Biotherapeutics inc   1.04 $ 110.768  Millions$ 106.848  Millions
Liminatus Pharma Inc   0.99 $ 3.017  Millions$ 3.040  Millions
Elutia Inc   0.95 $ 19.896  Millions$ 21.045  Millions
Jasper Therapeutics Inc   0.93 $ 7.314  Millions$ 7.845  Millions
Protalix Biotherapeutics inc   0.90 $ 28.140  Millions$ 31.391  Millions
Vivosim Labs Inc   0.88 $ 1.670  Millions$ 1.893  Millions
Senti Biosciences Holdings Inc   0.83 $ 13.124  Millions$ 15.765  Millions

Date modified: 2026-09-08T22:50:08+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.